Sunshine Biopharma Inc. 8-K

What Happened
Sunshine Biopharma Inc. (SBFM) filed an 8-K reporting that on May 28, 2026 Dr. Steve N. Slilaty — the Company’s CEO and holder of about 86% of voting power — approved by written consent several actions related to the Company’s recent public offering that closed May 19, 2026. The consent authorizes issuing in excess of 20% of the Company’s outstanding common stock at a deemed discount to the Nasdaq Minimum Price (per Nasdaq Listing Rule 5635(d)(1)(A)) as of the Placement Agent Agreement execution, and permits adjustments to the exercise price or number of shares underlying the Series C Warrants (per Sections 3.7 and 3.8 of the Series C Warrants). The consent becomes effective 20 days after the definitive information statement relating to it is mailed to stockholders.

Key Details

• Date of consent: May 28, 2026; Offering closed: May 19, 2026.
• Controller: Dr. Steve N. Slilaty holds ~86% of total voting power and is the consenting stockholder.
• Authorization: Issue in excess of 20% of outstanding common stock at a deemed discount to the Nasdaq Minimum Price.
• Warrant provisions: Approval to adjust exercise price/number of shares on a Share Combination Event (Section 3.7) and to voluntarily adjust Series C warrant exercise price from time to time (Section 3.8).

Why It Matters
For investors, this consent clears the way for additional share issuance above the 20% threshold and gives flexibility to modify Series C warrant economics. That can increase potential dilution for existing shareholders and affects the terms under which warrant holders may convert to stock. Because the approving vote came from the CEO who controls ~86% of voting power, the action reflects the decision of a controlling shareholder rather than a broad shareholder vote. The consent’s effectiveness is tied to mailing of an information statement (effective 20 days after mailing), so timing and any subsequent disclosures could be relevant for trading and dilution expectations.